interleukin receptor common gamma subunit

Summary

Summary: An interleukin receptor subunit that was originally discovered as a component of the INTERLEUKIN 2 RECEPTOR. It was subsequently found to be a component of several other receptors including the INTERLEUKIN 4 RECEPTOR, the INTERLEUKIN 7 RECEPTOR, the INTERLEUKIN-9 RECEPTOR, the INTERLEUKIN-15 RECEPTOR, and the INTERLEUKIN-21 RECEPTOR. Mutations in the gene for the interleukin receptor common gamma chain have been associated with X-LINKED COMBINED IMMUNODEFICIENCY DISEASES.

Top Publications

  1. Nieborowska Skorska M, Hoser G, Hochhaus A, Stoklosa T, Skorski T. Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice. Leukemia. 2013;27:2253-4 pubmed publisher
  2. Ivanisevic J, Epstein A, Kurczy M, Benton P, Uritboonthai W, Fox H, et al. Brain region mapping using global metabolomics. Chem Biol. 2014;21:1575-84 pubmed publisher
    ..This study helps define regional homeostasis for the normal mouse brain to give context to the reaction to pathological events. ..
  3. Geraghty N, Belfiore L, Ly D, Adhikary S, Fuller S, Varikatt W, et al. The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-? in a humanized mouse model of graft-versus-host disease. Clin Exp Immunol. 2017;190:79-95 pubmed publisher
    ..In conclusion, the P2X7 antagonist BBG reduced circulating IFN-? in a humanized mouse model of GVHD supporting a potential role for P2X7 to alter the pathology of this disease in humans. ..
  4. Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE. 2017;12:e0179431 pubmed publisher
    ..The model accurately describes the sustained in vivo signaling observed after a single dose of NKTR-214 and explains how the properties of NKTR-214 impart a unique kinetically-controlled immunological mechanism of action. ..
  5. Alhaj Hussen K, Vu Manh T, Guimiot F, Nelson E, Chabaane E, Delord M, et al. Molecular and Functional Characterization of Lymphoid Progenitor Subsets Reveals a Bipartite Architecture of Human Lymphopoiesis. Immunity. 2017;47:680-696.e8 pubmed publisher
    ..On the basis of these results, we propose a "two-family" model of human lymphoid development that differs from the prevailing model of hematopoiesis. ..
  6. Gutierrez Aranda I, Ramos Mejia V, Bueno C, Muñoz Lopez M, Real P, Macia A, et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells. 2010;28:1568-70 pubmed publisher
  7. Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q. Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett. 2014;344:13-19 pubmed publisher
    ..In this review, we discuss the use of NOD-SCID-IL2rg(–/–) mice as a preclinical tool in cancer research and its potential use for individualized cancer therapies. ..
  8. Mitiushova E, Shatrova A, Zenin V, Aksenov N, Marakhova I. [The STAT5 signaling in the expression of alpha-subunit of interleukin-2 receptor in human blood lymphocytes]. Tsitologiia. 2013;55:421-9 pubmed
    ..It has been concluded that JAK3/STAT5 signaling via IL-2 receptor is necessary to maintain the long-term expression of the high-affinity αβγ(c)-receptor of IL-2 and optimal proliferation of HBL. ..
  9. Berahovich R, Xu S, Zhou H, Harto H, Xu Q, Garcia A, et al. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells in vitro and in vivo. Front Biosci (Landmark Ed). 2017;22:1644-1654 pubmed
    ..CD19-FLAG CAR-T cells also significantly reduced Raji tumor burden and extended mouse survival. These results demonstrate the strong efficacy of FLAG-tagged CD19 CAR-T cells in solid and hematological cancer models. ..

More Information

Publications16

  1. Nowlan B, Futrega K, Brunck M, Walkinshaw G, Flippin L, Doran M, et al. HIF-1α-stabilizing agent FG-4497 rescues human CD34+ cell mobilization in response to G-CSF in immunodeficient mice. Exp Hematol. 2017;52:50-55.e6 pubmed publisher
    ..These results suggest that the PHD inhibitor FG-4497 also increases human HSPC mobilization in a xenograft mouse model, suggesting the possibility of testing PHD inhibitors to boost HSPC mobilization in response to G-CSF in humans. ..
  2. Giessler K, Kleinheinz K, Huebschmann D, Balasubramanian G, Dubash T, Dieter S, et al. Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med. 2017;214:2073-2088 pubmed publisher
    ..This demonstrates that functional heterogeneity is, at least frequently, present within genomic subclones and independent of mutational subclone differences. ..
  3. Shigemura T, Motobayashi M, Matsuda K, Shimodaira T, Kurata T, Kobayashi N, et al. Acute Myeloid Leukemia in a Patient With X-linked Severe Combined Immunodeficiency. J Pediatr Hematol Oncol. 2017;39:e470-e472 pubmed publisher
    ..Somatic NRAS mutation was detected at 3 months post-CBT. Thus, 6q- and NRAS mutation were strongly associated with the leukemic transformation in our patient. ..
  4. Resende M, Cardoso M, Ribeiro A, Flórido M, Borges M, Castro A, et al. Innate IFN-?-Producing Cells Developing in the Absence of IL-2 Receptor Common ?-Chain. J Immunol. 2017;199:1429-1439 pubmed publisher
    ..Overall, our results demonstrate that a population of Thy1.2+ non-NK innate-like cells present in the liver expresses IFN-? and can confer protection against M. avium infection in immunocompromised mice. ..
  5. Bustamante A, López Cancio E, Pich S, Penalba A, Giralt D, García Berrocoso T, et al. Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study. Stroke. 2017;48:2419-2425 pubmed publisher
    ..Additional discovery of new biomarkers and improvement on laboratory techniques seem necessary for achieving a molecular diagnosis of stroke. ..
  6. Li X, Nelson C, Nair R, Hazlehurst L, Moroni T, Martínez Acedo P, et al. Stable and Potent Selenomab-Drug Conjugates. Cell Chem Biol. 2017;24:433-442.e6 pubmed publisher
    ..These site-specific antibody-drug conjugates built on a selenocysteine interface revealed broad therapeutic utility in liquid and solid malignancy models. ..
  7. Meghnem D, Morisseau S, Frutoso M, Trillet K, Maillasson M, Barbieux I, et al. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15R?/?c Receptor. J Immunol. 2017;198:4563-4568 pubmed publisher
    ..Interestingly, due to the presence of IL-2R?, BiG had no impact on IL-2-dependent regulatory T cell proliferation. Thus, by acting as a fine switch in the immune system, BiG emphasizes the differential roles of these two cytokines. ..